Radioresistant malignant myoepithelioma of the breast with high level of ataxia telangiectasia mutated protein

J Med Imaging Radiat Oncol. 2009 Apr;53(2):234-9. doi: 10.1111/j.1754-9485.2009.02053.x.

Abstract

Malignant myoepithelioma of the breast (MMB) is a rare and often aggressive disease with poor prognosis. Little is known regarding its optimal treatment and progression. We describe the clinical history of a woman following excision of a benign adenomyoepithelioma which recurred years later as a radioresistant malignant myoepithelioma with high levels of ataxia telangiectasia mutated protein and mutant p53 (Cys135Phe). MMB requires close follow-up and aggressive treatment. If adjuvant radiotherapy is adopted to improve local control, minimal postoperative delay and higher doses than for standard post-mastectomy radiation are recommended.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ataxia Telangiectasia Mutated Proteins
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / radiotherapy*
  • Cell Cycle Proteins / analysis*
  • DNA-Binding Proteins / analysis*
  • Female
  • Humans
  • Middle Aged
  • Myoepithelioma / radiotherapy*
  • Protein Serine-Threonine Kinases / analysis*
  • Treatment Failure
  • Tumor Suppressor Proteins / analysis*

Substances

  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • Tumor Suppressor Proteins
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases